Innovent is a leading biopharmaceutical company ... National Enterprise for Investment", and "National Torch Program High-Tech Enterprises". For more information, visit www.ask-pharm.com.

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with Roche (OTCQX:RHHBY) to develop its experimental lung cancer therapy ...

Developed leveraging Innovent's proprietary novel topoisomerase 1 inhibitor (TOPO1i) platform, IBI3009 is one of the leading and potentially best-in-class DLL3-targeting ADCs. IBI3009 has shown ...

Innovent Biologics (OTCPK:IVBIY) announced that Chinese regulators have approved its second marketing application for lung cancer therapy, Dovbleron, developed with U.S. biotech Nuvation Bio (NYSE ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Roche's Chugai turns to Swiss biotech Araris for ADC deal potentially worth over $780M Boehringer plans to leverage Synaffix's tech to broaden ... Genmab, Innovent Biologics and many others.

SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Mankind Pharma Limited on Thursday announced that it has entered into a partnership with Innovent Biologics to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...